Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
about
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancerNon-steroidal antiandrogens compared to LHRH agonists or surgical castration therapy for advanced prostate cancerManagement of patients with biochemical recurrence after local therapy for prostate cancerSystemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.Hormone naïve prostate cancer: predicting and maximizing response intervalsOxidative stress in prostate cancer patients: A systematic review of case control studiesCrkI and p130(Cas) complex regulates the migration and invasion of prostate cancer cellsEfficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-AnalysisA review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ″perpetual dispute″.MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancerA double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians.Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancerCognitive impairment in men treated with luteinizing hormone-releasing hormone agonists for prostate cancer: a controlled comparisonLong-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen.Use of androgen deprivation therapy for metastatic prostate cancer in older men.Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancerPreoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.Androgen deprivation therapy for prostate cancer: indications, contraindications and possible consequences.Androgen deprivation therapy for prostate cancer-review of indications in 2010Cardiac and cognitive effects of androgen deprivation therapy: are they real?The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reductionAndrogen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.Cytoreductive prostatectomy: evidence in support of a new surgical paradigm (Review)Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review.CYP17A1 inhibitors in castration-resistant prostate cancerAndrogen receptors beyond prostate cancer: an old marker as a new target.SEOM clinical guidelines for the treatment of metastatic prostate cancerDenosumab in men receiving androgen-deprivation therapy for prostate cancerManagement of complications of androgen deprivation therapy in the older man.Inhibitory effect of dietary atorvastatin and celecoxib together with voluntary running wheel exercise on the progression of androgen-dependent LNCaP prostate tumors to androgen independenceRisk stratification in the hormonal treatment of patients with prostate cancerCognitive effects of hormone therapy in men with prostate cancer: a reviewSipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments.Androgen receptor signaling in prostate cancer development and progression.Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up studyInhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer.
P2860
Q24193722-7244EFA5-8F5F-46AA-9472-DAA03B324BCDQ24235190-888D6933-D28A-41D5-9D86-B34CBB800DF3Q26849220-2771CE3B-C5AD-422E-B465-93B92ADC7FA1Q26852544-659B9AC1-404F-49AB-8DC4-DB79DC2DEE8DQ27015904-016E8AF8-8F02-4891-8FA0-6D2DA34CC454Q28068523-7B81856D-BB0E-4935-BD49-5CB68B45AA36Q28254665-E5F85421-A3D1-4904-B2C9-B0BE05BC122CQ28550301-EABCCC8E-8AED-42D3-B09B-F679685C42A7Q30780322-159CCBEE-9EB1-4563-BE64-A576149C65E7Q33443571-E68D84A1-516F-4E59-B10D-C5FAA4BD1839Q33725993-2E742E10-9780-40ED-8EDC-0DFBC9944088Q33803812-C0BE1B86-2BB6-4648-BDF9-21201501D89AQ33823702-1EF61216-9696-4E97-8C11-6E19D9EAE0B4Q33878106-1769A985-E45F-489B-84B8-753A416A0ED4Q33965472-A8403447-EF0C-48FA-B309-D5B4C88CB7BCQ33977514-1168EEBC-C6F8-468C-909C-6474B88EA4A9Q33977523-864E4A9A-9B87-4FB4-8AF1-E9C9A0151A02Q33978286-922AAAD6-7974-4A65-9990-F78281774356Q34013761-9180AD8D-8CF0-48D6-B03D-5D64A8569246Q34062385-DE52F7E8-3589-4B1F-A841-8CD99ED07B3FQ34111603-158AFEC1-24F9-4662-AF6F-44690AD2CAE8Q34111628-C9E53D5F-F310-4658-B8FC-B345F8E4FC79Q34127128-B10C998E-08F3-4B00-B3A8-24EA818B0754Q34310143-7F18BE4F-78B7-4E8F-AA67-624CD094AAACQ34362184-DF7FD033-3807-4677-B6C3-6849DBB87A96Q34363785-14F56FA7-E970-409D-8DE2-CB6565FA7183Q34432859-2BE40837-8681-4A95-9571-DB4A0F47920CQ34454697-0C9BCA08-FB8C-407D-A8FC-6F2B11802934Q34456638-A89241BF-FD9A-4410-9645-EC31B2F08920Q34458538-368C31B1-311F-4DB7-B371-D33A10FDC2F5Q34553405-C71DA3EF-400A-4878-BCF0-4C1C2F9363E2Q34570396-13E2C4E2-9CFD-4DF4-AEEA-CE198BC0DDEAQ34782101-C7B4779B-8205-42F0-A05E-E8BAEAF69921Q35030507-0CE59322-64B5-4AD5-9B3F-702472086A0BQ35076189-A3AC285E-39A1-4CCC-AC3B-6D3C0EC5575DQ35098762-55345393-A192-4B9B-AAB2-6842AB5ADD7CQ35128716-B78A9EF6-1626-48A6-A140-E3AB98F94D7AQ35183663-A0F1E8BA-3F08-49DB-8BD5-34F2F9FCAADAQ35470434-F17378F3-647C-4FFF-A702-5F146793426AQ35551899-08AB6C4C-9B7E-419A-95D2-B566A320FB4E
P2860
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Initial hormonal management of ...... l Oncology practice guideline.
@ast
Initial hormonal management of ...... l Oncology practice guideline.
@en
type
label
Initial hormonal management of ...... l Oncology practice guideline.
@ast
Initial hormonal management of ...... l Oncology practice guideline.
@en
prefLabel
Initial hormonal management of ...... l Oncology practice guideline.
@ast
Initial hormonal management of ...... l Oncology practice guideline.
@en
P2093
P356
P1476
Initial hormonal management of ...... l Oncology practice guideline.
@en
P2093
Charles L Bennett
D Andrew Loblaw
David S Mendelson
Howard I Scher
James L Wade
James Talcott
Katherine S Virgo
Mark R Somerfield
Maryellen Taplin
Nicholas J Vogelzang
P304
P356
10.1200/JCO.2006.10.1949
P407
P577
2007-04-02T00:00:00Z